S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.54
+1.86
+11.15%
BIOA · BioAge Labs, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
BIOAGE Labs Inc (BIOA)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$5.51
-0.04
(-0.81%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$5.51
$5.43
$5.67
52-WEEK RANGE
$5.51
$4.81
$25.95
What's happening
- BIOA is down 0.81% today, trading at $5.51. — Live quote
- Volume today (54,902) is well below its 3-month average of 880,910. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.58 actual vs. $-0.62 estimated (+7.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 6
Buy 6
Hold 3
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (15 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
BIOA
-58.35%
vs S&P 500
-71.72%
1-YEAR RETURN
BIOA
+3.96%
vs S&P 500
-11.20%
6-MONTH RETURN
BIOA
-70.20%
3-MONTH RETURN
BIOA
-74.89%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.58
Est. $-0.62
BEAT +7.1%
2026-04-26 (Q1 2026)
$-0.52
Est. $-0.65
BEAT +20.3%
2026-01-26 (Q4 2025)
$-0.72
Est. $-0.75
BEAT +4.5%
2025-10-26 (Q3 2025)
$-0.56
Est. $-0.60
BEAT +6.0%
Valuation Measures & Ratios
Enterprise Value4$178.9M
Forward P/E5—
PEG Ratio6-0.34
Price / Sales (TTM1)24.42
Price / Book72.91
EV4 / Revenue17.28
EV4 / EBITDA—
Profit Margin-912.25%
Operating Margin-1026.28%
Return on Equity (ROE8)-28.99%
Return on Assets (ROA9)-27.09%
Avg Volume (3M)880,910
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $1.10B | $748.7M | $213.6M | $148.6M | $134.7M |
| P/E | -12.24 | -9.73 | -2.74 | -2.08 | -2.14 |
| Price/Sales | 113.78 | 86.16 | 36.10 | 38.47 | — |
| Price/Book | 2.94 | 1.97 | 0.77 | 0.50 | 0.43 |
| EV/Revenue | 106.14 | 58.47 | 0.36 | -17.12 | — |
| ROE | -24.03% | -20.29% | -28.14% | -24.25% | -20.09% |
| ROA | -22.70% | -19.34% | -25.59% | -22.19% | -18.30% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short3,274,379
Change from Prior Settlement+6.52%
% of Float—
Days to Cover (Short Ratio)3.94
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 1.6% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is +4.0%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -912.2%. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-10-02; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on BIOA
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5M | $2.8M | $2.1M | $2.4M | $1.5M | $0 | $0 | — |
| Operating income | -$29.3M | -$25.4M | -$23.1M | -$24.8M | -$16.4M | -$24.8M | -$15.3M | -$12.8M |
| Net income | -$26.1M | -$22.3M | -$20.2M | -$21.6M | -$12.9M | -$23.4M | -$13.6M | -$13.0M |
| EPS (diluted) | $-0.58 | $-0.52 | $-0.56 | $-0.60 | $-0.36 | $-6.70 | $-7.94 | $-7.76 |
| EPS (basic) | $-0.58 | $-0.52 | $-0.56 | $-0.60 | $-0.36 | $-6.70 | $-7.94 | $-7.76 |
| Operating margin | -$1.2K | -$915 | -$1.1K | -$1.0K | -$1.1K | — | — | — |
| Net margin | -$1.1K | -$803 | -$982 | -$894 | -$891 | — | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $396.9M | $397.7M | $294.9M | $305.1M | $322.1M | $343.8M | $358.2M | $337.4M |
| Total liabilities | $22.0M | $18.5M | $22.8M | $27.6M | $27.4M | $30.7M | $35.1M | $23.6M |
| Stockholders' equity | $374.9M | $379.1M | $272.1M | $277.5M | $294.8M | $313.2M | $323.1M | $313.7M |
| Total current assets | $330.3M | $391.9M | $286.8M | $290.8M | $301.7M | $324.8M | $357.1M | $336.5M |
| Total current liabilities | $19.2M | $15.8M | $20.1M | $24.5M | $22.8M | $23.7M | $27.8M | $19.1M |
| Cash & equivalents | $74.0M | $241.8M | $188.9M | $215.6M | $220.3M | $257.5M | $354.3M | $334.5M |
| Marketable securities (current) | $244.8M | $141.4M | $92.2M | $70.2M | $77.0M | $63.0M | $0 | — |
| Accounts receivable | $625.0K | $709.0K | $769.0K | $515.0K | $603.0K | $361.0K | $0 | — |
| Marketable securities (non-current) | $62.5M | $1.7M | $4.0M | $10.1M | $16.1M | — | — | — |
| Property, plant & equipment | $1.2M | $1.1M | $963.0K | $973.0K | $974.0K | $929.0K | $591.0K | $543.0K |
| Other non-current assets | $208.0K | $215.0K | $216.0K | $227.0K | $237.0K | $239.0K | $240.0K | — |
| Accounts payable | $5.7M | $3.1M | $2.7M | $5.0M | $1.3M | $4.0M | $2.0M | $2.1M |
| Deferred revenue (current) | $4.4M | $6.2M | $5.8M | $7.5M | $7.7M | $8.2M | $7.8M | — |
| Short-term debt | $0 | $1.2M | $2.6M | $4.1M | $5.6M | $6.0M | $6.0M | $6.0M |
| Long-term debt | — | — | $0 | $0 | $0 | $1.1M | $2.5M | $3.9M |
| Common stock & paid-in capital | $0 | $0 | $0 | $0 | $0 | — | $0 | — |
| Retained earnings | -$381.8M | -$355.7M | -$333.4M | -$307.5M | -$287.3M | -$265.7M | -$252.8M | -$231.7M |
| Accumulated other comprehensive income (loss) | -$478.0K | $73.0K | $278.0K | $275.0K | $212.0K | $264.0K | $245.0K | $109.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$19.3M | -$24.0M | -$28.3M | -$16.0M | -$20.0M | -$17.4M | -$5.1M | -$14.9M |
| Investing cash flow | -$164.5M | -$46.8M | -$14.4M | $12.8M | -$15.6M | -$78.0M | -$26.0K | -$305.0K |
| Financing cash flow | $16.0M | $123.7M | $16.0M | -$1.5M | -$1.5M | -$1.5M | $24.9M | $190.7M |
| Free cash flow | -$19.6M | -$24.1M | -$28.4M | -$16.1M | -$20.1M | -$17.8M | -$5.2M | -$15.2M |
| Capital expenditures | $328.0K | $26.0K | $112.0K | $22.0K | $159.0K | $426.0K | $26.0K | $305.0K |
| Share-based compensation | $4.3M | $4.3M | $2.7M | $2.8M | $3.2M | $2.9M | $2.7M | $1.8M |
| Change in accounts receivable | -$84.0K | -$60.0K | $254.0K | -$88.0K | $242.0K | $361.0K | $0 | $0 |
| Change in accounts payable | $2.6M | $326.0K | -$2.3M | $3.6M | -$2.6M | $2.0M | -$126.0K | $1.3M |
| Purchases of investments | $203.8M | $80.2M | $40.3M | $12.9M | $24.0M | $77.6M | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $9.0M | $0 | — |
| Operating income | -$92.8M | -$78.2M | -$48.4M |
| Net income | -$80.6M | -$71.1M | -$63.9M |
| EPS (diluted) | $-2.24 | $-6.63 | $-38.17 |
| EPS (basic) | $-2.24 | $-6.63 | $-38.17 |
| Operating margin | -$1.0K | — | — |
| Net margin | -$896 | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|
| Total assets | $294.9M | $358.2M | $25.9M | — |
| Total liabilities | $22.8M | $35.1M | $66.6M | — |
| Stockholders' equity | $272.1M | $323.1M | -$173.4M | -$112.6M |
| Total current assets | $286.8M | $357.1M | $25.3M | — |
| Total current liabilities | $20.1M | $27.8M | $58.2M | — |
| Cash & equivalents | $188.9M | $354.3M | $21.6M | — |
| Marketable securities (current) | $92.2M | $0 | — | — |
| Accounts receivable | $769.0K | $0 | — | — |
| Marketable securities (non-current) | $4.0M | — | — | — |
| Property, plant & equipment | $963.0K | $591.0K | $323.0K | — |
| Other non-current assets | $216.0K | $240.0K | — | — |
| Accounts payable | $2.7M | $2.0M | $1.9M | — |
| Deferred revenue (current) | $5.8M | $7.8M | — | — |
| Short-term debt | $2.6M | $6.0M | $6.0M | — |
| Long-term debt | $0 | $2.5M | $8.2M | — |
| Common stock & paid-in capital | $0 | $0 | $0 | — |
| Retained earnings | -$333.4M | -$252.8M | -$181.7M | — |
| Accumulated other comprehensive income (loss) | $278.0K | $245.0K | $164.0K | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Operating cash flow | -$81.6M | -$51.5M | -$37.4M |
| Investing cash flow | -$95.2M | -$366.0K | -$266.0K |
| Financing cash flow | $11.5M | $381.2M | $34.9M |
| Free cash flow | -$82.3M | -$51.9M | -$37.5M |
| Capital expenditures | $719.0K | $366.0K | $166.0K |
| Share-based compensation | $11.7M | $7.0M | $3.0M |
| Change in accounts receivable | $769.0K | $0 | — |
| Change in accounts payable | $788.0K | $6.0K | -$393.0K |
| Purchases of investments | $154.7M | $0 | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding BIOA as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-12-04 to 2026-06-30
Recent transactions
- Insiders have net sold 62,566 shares over the last 182 days, across 0 purchases and 2 sales.
- Most recent: Barton Shane (Principal Accounting Officer) — Option exercise of 4,290 shares on 2026-06-30.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)62,566 sh(2 txns)
Net Shares-62,566
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Barton Shane | Principal Accounting Officer | Option exercise | 2026-06-30 | 4,290 |
| GOLDSTEIN DOV A MD | Chief Financial Officer | Option exercise | 2026-04-23 | 3,542 |
| RUBIN PAUL D | Chief Medical Officer | Option exercise | 2026-04-01 | 5,437 |
| Fortney Kristen | Chief Executive Officer | Open market sale | 2026-01-13 | 233,107 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-30 | Barton Shane | Principal Accounting Officer | Option exercise | 4,290 | $10.85 |
| 2026-06-30 | Barton Shane | Principal Accounting Officer | Option exercise | 4,000 | $8.39 |
| 2026-06-30 | Barton Shane | Principal Accounting Officer | Option exercise | 4,065 | $4.30 |
| 2026-06-30 | Barton Shane | Principal Accounting Officer | Option exercise | 7,861 | $4.38 |
| 2026-06-30 | Barton Shane | Principal Accounting Officer | Open market sale | 20,216 | $25.19 |
| 2026-06-29 | Barton Shane | Principal Accounting Officer | Option exercise | 9,301 | $10.85 |
| 2026-06-29 | Barton Shane | Principal Accounting Officer | Option exercise | 7,261 | $8.39 |
| 2026-06-29 | Barton Shane | Principal Accounting Officer | Option exercise | 8,958 | $4.30 |
| 2026-06-29 | Barton Shane | Principal Accounting Officer | Option exercise | 14,198 | $4.38 |
| 2026-06-29 | Barton Shane | Principal Accounting Officer | Open market sale | 42,350 | $25.21 |
| 2026-04-23 | GOLDSTEIN DOV A MD | Chief Financial Officer | Option exercise | 3,542 | $4.38 |
| 2026-04-01 | RUBIN PAUL D | Chief Medical Officer | Option exercise | 5,437 | $4.11 |
| 2026-04-01 | RUBIN PAUL D | Chief Medical Officer | Option exercise | 3,383 | $6.57 |
| 2026-04-01 | RUBIN PAUL D | Chief Medical Officer | Open market sale | 8,820 | $17.81 |
| 2026-03-02 | RUBIN PAUL D | Chief Medical Officer | Option exercise | 5,433 | $4.11 |
| 2026-03-02 | RUBIN PAUL D | Chief Medical Officer | Option exercise | 2,000 | $6.57 |
| 2026-03-02 | RUBIN PAUL D | Chief Medical Officer | Open market sale | 7,433 | $20.30 |
| 2026-03-01 | GOLDSTEIN DOV A MD | Chief Financial Officer | Option exercise | 3,542 | $4.38 |
| 2026-02-02 | RUBIN PAUL D | Chief Medical Officer | Option exercise | 5,433 | $4.11 |
| 2026-02-02 | RUBIN PAUL D | Chief Medical Officer | Option exercise | 2,000 | $6.57 |
| 2026-02-02 | RUBIN PAUL D | Chief Medical Officer | Open market sale | 7,433 | $18.75 |
| 2026-02-01 | GOLDSTEIN DOV A MD | Chief Financial Officer | Option exercise | 3,541 | $4.38 |
| 2026-01-16 | GOLDSTEIN DOV A MD | Chief Financial Officer | Option exercise | 3,542 | $4.38 |
| 2026-01-13 | GOLDSTEIN DOV A MD | Chief Financial Officer | Option exercise | 27,000 | $8.39 |
| 2026-01-13 | GOLDSTEIN DOV A MD | Chief Financial Officer | Open market sale | 8,974 | $18.43 |
| 2026-01-13 | GOLDSTEIN DOV A MD | Chief Financial Officer | Open market sale | 4,440 | $19.45 |
| 2026-01-13 | GOLDSTEIN DOV A MD | Chief Financial Officer | Open market sale | 11,663 | $20.54 |
| 2026-01-13 | GOLDSTEIN DOV A MD | Chief Financial Officer | Open market sale | 1,923 | $21.08 |
| 2026-01-13 | Fortney Kristen | Chief Executive Officer | Open market sale | 233,107 | $18.12 |
| 2026-01-02 | RUBIN PAUL D | Chief Medical Officer | Option exercise | 5,433 | $4.11 |
| 2026-01-02 | RUBIN PAUL D | Chief Medical Officer | Option exercise | 2,000 | $6.57 |
| 2026-01-02 | RUBIN PAUL D | Chief Medical Officer | Open market sale | 7,433 | $12.85 |
| 2025-12-09 | RUBIN PAUL D | Chief Medical Officer | Option exercise | 18,000 | $6.57 |
| 2025-12-09 | RUBIN PAUL D | Chief Medical Officer | Open market sale | 18,000 | $12.00 |
| 2025-12-04 | RUBIN PAUL D | Chief Medical Officer | Option exercise | 68,897 | $4.11 |
| 2025-12-04 | RUBIN PAUL D | Chief Medical Officer | Open market sale | 68,897 | $10.19 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 09:15 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-02 | 8-K | 2026-10-02 | View on SEC.gov → |
| 2026-08-05 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-05 | 8-K | 2026-08-05 | View on SEC.gov → |
| 2026-07-01 | 4 | 2026-06-29 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-10 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-10 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-10 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-10 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-10 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-10 | View on SEC.gov → |
| 2026-06-12 | 8-K | 2026-06-10 | View on SEC.gov → |
| 2026-05-08 | 8-K | 2026-05-08 | View on SEC.gov → |
Recent news
Headlines about BIOA (BioAge Labs, Inc.). Links open the publisher — we don’t host full articles.
-
(BIOA) Price Dynamics and Execution-Aware Positioning
Stock Traders Daily · 2026-10-18 -
Citi Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $21
Moomoo · 2026-10-15 -
Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target
Yahoo · 2026-10-14 -
BioAge Labs' Lead Drug Faces Uncertain Path as Data Looms, UBS Says
Yahoo · 2026-10-12 -
UBS Initiates Coverage On Bioage Labs with Neutral Rating, Announces Price Target of $8
Benzinga · 2026-10-12 -
BioAge Labs to Present at Upcoming Investor Conferences
Yahoo Finance · 2026-09-25 -
10 small-cap U.S. healthcare stocks with the weakest momentum grades
Seeking Alpha · 2026-09-18 -
BioAge Labs, Inc. (BIOA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha · 2026-09-16
No headlines in this category right now — try “All”.